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Introduction
Rapid developments in digital mobile and sensor technology
have facilitated the active and passive collection of detailed,
personalized data in increasingly affordable ways [1].
Researchers may be familiar with the daily diary, portable
computers, or the pedometer for the collection of patient-
reported outcomes (PRO) [2] in cancer survivorship research
[3]. Such methods, termed ecological momentary assessment
(EMA), have evolved with technological advances, e.g.,
collecting data or providing interventions (ecological momen-
tary intervention, EMI) via apps or devices such as
smartphones [4]. These smart technology–adapted sEMA/
sEMI methods are more widely used in affective disorders
or addictive behavior research [5, 6] but are currently still
under-utilized in cancer survivorship research. A recent scop-
ing review on the use of active EMA among cancer survivors
identified twelve articles published between 1993 and 2018
[7]. Most of the included studies in that review used portable
computers. This commentary will discuss the utility of sEMA/
sEMI in cancer survivorship research and call for action to
advance this area of science.
What is EMA?
EMA refers to an intensive method of collecting reports on
respondents’ current state [8]. It has also been termed as
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“experience sampling” or “diary assessment” [8, 9]. Although
these terms stress different aspects of EMA, collectively, they
encompass methods that involve the “repeated sampling of
people’s current thoughts, emotions, behavior, physiological
states, and context, in their natural environment, typically (but
not necessarily) via electronic wearable devices” [8].
EMA methods can be categorized as being either active or
passive. Active EMA requires conscious input from the par-
ticipants who are prompted to provide information multiple
times a day and, typically, over a period of consecutive days
[8]. Passive EMA collects observational data through wear-
able devices/sensors (e.g., pedometers, fitness trackers) with-
out participants’ active involvement [10]. Technological ad-
vances in smart devices have broadened the range of data
collected with passive EMA tracking. These “digital pheno-
types” can be accessed with in-built sensors (e.g., accelerom-
eter, gyroscope, heart rate measurements) or log files data
(location tracking, screen activity tracking) [11].
Why use EMA?
A key feature of EMA is that data is collected in participants’
natural, lived environments (“ecological validity”), as op-
posed to data collected within a research or laboratory setting
[8]. Health behaviors and experiences can be affected by con-
text, and such information is difficult to capture in traditional
retrospective assessments. EMA methods have notably fur-
thered the science of substance use, cessation, and relapse,
often with results in contrast to theory-driven studies that are
largely derived from global reports collected with retrospec-
tive questionnaires [12, 13].
In light of the recent movement to implement the use of
PRO in clinical routine care [14], including electronically cap-
tured PRO (ePRO) via mobile apps [15], it is important to
differentiate the nature of clinical use of PRO versus active
EMA. Traditional methods of collecting PRO for clinical use
tend to rely on global retrospective self-reports, e.g., using a
time frame of past 24 h or week. Such measures are often used
on a regular basis or immediately prior to clinic visits for
pragmatic reasons [16], due to technical/administrative con-
siderations or to minimize possible disruption to clinical
workflow [14]. The main drawback of such assessments is
recall bias [8]. Active EMA circumvents this problem by ask-
ing participants to rate their current state (“momentary”) rather
than reflect on aggregated, past experiences. Furthermore,
EMA involves repeated assessments at different times per
day for consecutive days. This allows the capture of the dy-
namic changes in symptomatology and behavior or mental
states through the interplay with environment, context, social
relationships, and time [8]. As an example, cancer-related fa-
tigue could vary depending on time and context [17]. Also,
cancer survivors often experience multiple symptoms which
can persist indefinitely [18]. EMA could be a less cumber-
some and cost-effective alternative to traditional PRO
methods in the longitudinal collection of complex multidi-
mensional constructs [10].
sEMA applications in cancer survivorship
In clinical setting
sEMA offers significant potential for diagnostic, monitoring,
or intervention purposes in the clinical setting.
Active and passive sEMA data can be incorporated in a
study to assess effects of diagnosis [19], in active cancer treat-
ment [20], or in a palliative setting. Accelerometer data col-
lected from smartphones could track recovery trajectories
such as physical activity following cancer treatment beyond
traditional clinical indicators [21] or to support behavioral
change [22]. Semantic location data comprising information
from smartphone sensors (sound, light, WiFi signals) and
global positioning system tracking have explored associations
between physical activity and mental health [23].
The advantages of sEMA can also be leveraged in symp-
tom management where continuous monitoring of side effects
is of relevance [24]. A novel pilot study uses a package of
wireless sensing technologies to collect passive (physiologic
and environmental/home ambient factors) and active (subjec-
tive experience of pain episode) data that could influence
cancer-related pain [25]. Passive sleep monitoring using
smartphone sensors offers a potential simpler and cheaper
solution to traditional methods to assess sleep problems [26],
which is significant in cancer survivors.
An outgrowth of sEMA, sEMI aims to provide interven-
tions remotely in respondents’ everyday lives (i.e., real time)
and natural environments. sEMI can be tailored to provide
feedback to enhance treatment personalization and adherence,
e.g., providing an sEMI following an sEMA on affect or
health behavior [27]. Despite a significant increase of
e-health/m-health interventions in cancer care [28], assessment
of their usage and adherence is not optimal [29]. Integration of
sEMA methods such as Just-In-Time Adaptive Interventions
can potentially benefit e-health/m-health interventions, [29] as
evidenced in studies with psychiatric populations [30] or in
weight management [31].
In research setting
The smartphone is now almost ubiquitous, reducing the need
for additional equipment. sEMA could potentially reach pop-
ulations previously under-researched using traditional data
capture methods, e.g., living in remote/rural areas. EMA can
collect large amounts of quantitative ideographic (individual)
data [10]. Traditional quantitative methods tend to be
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nomothetic, identifying patterns of behavior across a popula-
tion of individuals [10]. However, group-level findings may
not generalize to the individual [10]. Quantitative ideographic
data is especially clinically relevant in the current strive to
provide personalized cancer care.
Cancer survivors often experience co-occurring multiple
symptoms, e.g., the cluster of sleep problem, fatigue, and de-
pression, of which a challenge exists to identify the “driver” or
trigger symptom of these clusters [32]. According to the
Network Theory of Psychopathology, recurrent causal loops
maintain the “disordered” state (e.g. sleep problem→ fatigue
→ rumination → sleep problem) [10]. These self-sustaining
loops could be broken by targeting personalized interventions
to the identified patient-specific symptom networks [33].
Identification of such networks require ecologically valid re-
peated assessments of symptoms, for which EMA is well-
suited [10].
Conclusion
Rapid advances in technology and a marked interest in per-
sonalized health care could increase the feasibility and attrac-
tiveness of sEMA in cancer survivorship research.
Nevertheless, challenges of EMA studies such as reproduc-
ibility, comparability of assessment items, and interpretation
of results exist [7]. Other concerns such as data provenance
and regulatory issues also need to be addressed in light of the
growing interest of sEMA in cancer survivorship research
[34]. To further advance this field of science and practice,
some recommendations include (1) the use of a checklist
(e.g., an adapted STROBE checklist) [35] to report ongoing
sEMA studies, (2) initiate a Delphi survey to identify areas of
focus for the development of best practice guidelines, and (3)
the clinical and research community could establish an inter-
national interdisciplinary working group similar to the work-
ing groups that sought consensus for use of patient-reported
outcomes in research and clinical practice [36]. A working
group for sEMA could involve expertise representing oncol-
ogy in clinical practice, research, m-health, implementation
science, and consumers to (1) inventory the use of sEMA in
cancer survivorship research and to systematically identify
potential barriers and solutions of its usage; (2) identify qual-
ity hallmarks of apps and platform providers of sEMA in view
of the current proliferation; (3) develop guidelines on the de-
sign, methodology, and statistical analyses of sEMA studies;
and (4) provide guidance on addressing relevant ethical con-
cerns associated with the use of sEMA. Such guidance should
include, but not limited to, ethical considerations of using
smart sensors/devices; the collection, storage, and sharing of
sEMA data [10]; and the benefits versus patient burden in the
use of sEMA [37].
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